Market capitalization | €1.07b |
Enterprise Value | €1.01b |
P/E (TTM) P/E ratio | 11.04 |
EV/FCF (TTM) EV/FCF | 19.76 |
EV/Sales (TTM) EV/Sales | 2.13 |
P/S ratio (TTM) P/S ratio | 2.26 |
P/B ratio (TTM) P/B ratio | 1.57 |
Dividend yield | 4.55% |
Last dividend (FY24) | €0.16 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Faes Farma SAReg forecast:
2 Analysts have issued a Faes Farma SAReg forecast:
Jun '24 |
+/-
%
|
||
Revenue | 476 476 |
7%
7%
|
|
Gross Profit | 196 196 |
12%
12%
|
|
EBITDA | 124 124 |
9%
9%
|
EBIT (Operating Income) EBIT | 104 104 |
11%
11%
|
Net Profit | 97 97 |
9%
9%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Faes Farma SA operates as a pharmaceutical company. It engages in manufacturing and sale of chemical and pharmaceutical products, as well as the acquisition, purchase, sale, investment, holding, administration, management, negotiation and leasing of companies, of transferable and immovable securities, patents, trademarks and registrations and social participations. The company was founded in 1933 and is headquartered in Leioa, Spain.
Head office | Spain |
CEO | Eduardo Cuadra |
Founded | 1933 |
Website | faesfarma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.